Abstract
Rituximab, identified through pivotal lymphoma research, was the first monoclonal antibody approved by the US FDA in 1997. Since the success of rituximab, monoclonal antibodies have been a major focus for development of targeted agents for lymphoma treatment. A major hurdle in the development of a new antibody is finding a new target antigen. CD30 is an attractive therapeutic target antigen, because it has been identified as a marker of Reed–Sternberg cells in Hodgkin lymphoma (HL) [1], it is known to be expressed on anaplastic large cell lymphoma (ALCL), some cases of mediastinal large cell lymphoma, primary effusion lymphoma and multiple myeloma. However, its expression on normal tissues is restricted to a small number of activated B- and T-lymphocytes [2]. Thus, based on its expression pattern, CD30 could be an ideal therapeutic target.
Highlights
Rituximab, identified through pivotal lymphoma research, was the first monoclonal antibody approved by the US FDA in 1997
In a phase I trial, one CR was reported in a patient with cutaneous anaplastic large cell lymphoma (ALCL) [4]
In a phase II trial for Hodgkin lymphoma (HL) or ALCL, 7 responses (2 CR, 5 PR) in patients with ALCL were reported in 79 patients
Summary
Rituximab, identified through pivotal lymphoma research, was the first monoclonal antibody approved by the US FDA in 1997. Naked CD30 targeting antibodies and modified/ engineered anti-CD30 antibodies CD30 is considered an ideal target, the results from early clinical trials with first-generation naked monoclonal antibodies targeting CD30 have been disappointing. SGN-30 is a chimeric anti-CD30 monoclonal antibody. In a phase I trial, one CR was reported in a patient with cutaneous ALCL [4].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
